TABLE 1

Genotype counts for HNF4A P2 SNP rs1884613 in each U.K. and Ashkenazi population

Control subjectsCase subjectsOR95% CIP
n111222111222
ASH (new)90 (65.69)41 (29.93)6 (4.38)200 (51.81)142 (36.79)44 (11.40)1.70141.23–2.360.0014*
ASH (old)217 (65.69)88 (27.41)16 (4.98)76 (54.68)57 (41.01)6 (4.32)1.55811.06–2.300.0248
CCC381 (72.16)138 (26.14)9 (1.70)375 (68.93)156 (28.68)13 (2.39)1.15960.92–1.470.2201
Exeter147 (71.71)55 (26.83)3 (1.46)152 (76.38)44 (22.11)3 (1.51)0.81730.54–1.230.3314
EPIC-Norfolk506 (68.94)209 (28.47)19 (2.59)239 (67.51)108 (30.51)7 (1.98)1.03310.81–1.320.7937
W2318 (71.30)110 (24.66)18 (4.04)338 (68.70)144 (29.27)10 (2.03)1.02180.80–1.300.861
Meta-analysis1,659 (69.97)641 (27.04)71 (2.99)1,380 (65.28)651 (30.79)83 (3.93)1.13940.90–1.450.2833
  • Data are genotype counts (frequencies) unless otherwise indicated. Genotype counts (and frequencies) are shown for those homozygous for the common allele (n = 11), heterozygous (n = 12), and homozygous for the minor allele (n = 22). ORs, 95% CIs, and P values are based on an additive model. For SNP rs1884613, there is a lower call rate for Exeter samples.

  • *

    * P <0.01. ASH (new), novel Ashkenazi samples not previously tested for association (138 control and 393 case subjects); ASH (old), Ashkenazi samples overlapping with those in the original report (ref. 2) (324 control and 143 case subjects); CCC, Cambridgeshire study; EPIC-Norfolk, European Prospective Investigation of Cancer-Norfolk; W2, Warren 2 Repository.